Louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely
The US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday.
Louisiana sued the US Food and Drug Administration (FDA) in October in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely, arguing that it interfered with the state’s ban on abortion.
In other words louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. Curious to see how this develops.
Reading that louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone — hard to argue with the logic there.
So the bottom line is the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Wonder how this will land.
Think about it: louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. That speaks volumes.
What stands out is the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. That is the part worth paying attention to.
When you look at the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday, the implications are hard to ignore.
The US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Meanwhile louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone.
What stands out is louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. That is the part worth paying attention to.
The bigger issue here is louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. That changes the calculation.
On one hand louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. But at the same time the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday.
In other words the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. Curious to see how this develops.
The bigger issue here is the US supreme court upheld nationwide access to mail-order mifepristone, an abortion medication, in a shadow-docket decision on Thursday. That changes the calculation.
When you look at louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone, the implications are hard to ignore.
The detail about louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone is something people should sit with.
Basically louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone. What matters is whether anything changes because of it.